You are here: Industry Insights > Samsung Biologics

News List

Samsung Biologics Unveils Strong Performance and Future Plans at its 10th Annual General Meeting of Shareholders prnasia
March 19, 2021
Samsung Biologics announced a strong year in 2020 as it reported 1 trillion won in target sales within just a decade at its 10th Annual General Meeting (AGM) on March 19th Korea time.
Samsung Biologics, National OncoVenture, and Eutilex Obtain IND Approval from FDA prnasia
January 27, 2021
Samsung Biologics announced another successful Investigational New Drug (IND) clearance from the FDA for its client to begin clinical trials on a cancer immunotherapy, furthering the company's track record as a premiere CDO service provider in the ...
Samsung Biologics Reports 66% Increase in 2020 Revenue Achieving "1 Trillion Won" Target Sales prnasia
January 26, 2021
Samsung Biologics reported its fourth quarter and full-year 2020 financial results indicating strong business performance, benefitting from increased sales across all plants and significant business agility and operating excellence in overcoming ...
Samsung Biologics Names John Rim as President and CEO contractpharma
December 17, 2020
Samsung Biologics has appointed John Rim as its president and chief executive officer. The appointment was made effective immediately and formalized via the company’s board of directors meeting yesterday.
Lilly, Samsung Partner to Mass Produce COVID-19 Antibody americanpharmaceuticalreview
November 25, 2020
Samsung Biologics' partnership with Eli Lilly and Company is expected to accelerate the global supply for Lilly's COVID-19 antibody therapies through a long-term manufacturing agreement, with the goal of making antibody treatments more globally ...
Samsung Biologics Breaks Ground on 'Super Plant' contractpharma
November 25, 2020
When completed, the CDMO says it will be the world's largest bio-manufacturing facility.
Samsung Biologics Partners with Eli Lilly contractpharma
November 23, 2020
Samsung Biologics has entered a strategic manufacturing partnership with Eli Lilly to accelerate the global supply for Lilly’s Covid-19 antibody therapies with the ultimate goal of making antibody treatments more globally accessible for patients.
Samsung Biologics signs Covid-19 therapy manufacturing deal with Lilly pharmaceutical-technology
November 18, 2020
South Korean pharma firm Samsung Biologics has entered a long-term agreement with Eli Lilly and Company to manufacture its investigational Covid-19 virus neutralising antibody, bamlanivimab.
Samsung Biologics Expands in China contractpharma
November 05, 2020
Samsung Biologics has entered into a partnership with GeneQuantum Healthcare, a China biotech company, to jointly develop an antibody drug conjugate (ADC) for the treatment of non-small-cell lung carcinoma (NSCLC), triple-negative breast cancer (TNBC)...
Samsung Biologics, Checkpoint Therapeutics Expand Cosibelimab Mfg. Pact contractpharma
November 04, 2020
Samsung Biologics and Checkpoint Therapeutics, Inc. have expanded a long-term manufacturing partnership for Checkpoint's anti-PD-L1 antibody, cosibelimab.

Previous page 1 2 3 4 5 6 Next page